Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Sees Significant Decline in Short Interest

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 9,900 shares, a decrease of 27.2% from the January 15th total of 13,600 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average trading volume of 34,700 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of Lakeshore Biopharma

A number of hedge funds have recently bought and sold shares of the business. FMR LLC acquired a new stake in Lakeshore Biopharma in the 3rd quarter valued at about $803,000. Hhlr Advisors LTD. acquired a new stake in Lakeshore Biopharma in the 3rd quarter valued at about $513,000. Finally, Barclays PLC acquired a new stake in Lakeshore Biopharma in the 3rd quarter valued at about $169,000. Institutional investors and hedge funds own 52.64% of the company’s stock.

Lakeshore Biopharma Price Performance

LSB stock traded down $0.01 during mid-day trading on Friday, reaching $2.40. The company’s stock had a trading volume of 3,906 shares, compared to its average volume of 8,274. The company has a quick ratio of 0.90, a current ratio of 1.17 and a debt-to-equity ratio of 0.13. Lakeshore Biopharma has a fifty-two week low of $1.88 and a fifty-two week high of $11.20. The company’s 50 day moving average is $2.78 and its two-hundred day moving average is $3.70.

About Lakeshore Biopharma

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.